The other mutations found in AML, such as FLT3-ITD (ITD, internal tandem duplication), FLT3-TKD (TKD, tyrosine kinase domain), NRAS, KRAS, IDH1, IDH2, and MLL-PTD may be lost between diagnosis and relapse as a result of clonal evolution of leukaemia, thus being unstable throughout treatment. This evidence concerns the gene FLT3 and leukemia.